The data on the sold production of antisera and vaccines in the UK shows notable fluctuations over the last decade. There was significant growth from 2013 to 2015, with a peak in 2015. Following this, the market saw a declining trend until 2020, aside from some intermittent rebounds. The latest figures show a slight recovery, standing at 864.12 million Euros in 2023. Over the last two years, there were modest fluctuations with a 2.08% increase in 2023 after a -2.7% decrease the previous year. The five-year CAGR from 2019 to 2023 indicates a slight decline of -2.4%.
Looking forward, the forecast for the next five years indicates a stable gradual growth with a CAGR of 1.58%, culminating in an 8.13% growth rate by 2028. This suggests the market will stabilize and experience steady growth in the medium term.
Future trends to watch for include advancements in biotechnology, government healthcare policies, and the impact of global health challenges like pandemics which could alter demand patterns and production capacities significantly.
